Clinical Trial Update: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 3 study of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, with results posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Endocyte | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-05-09